|
MechanismABCA1 stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Effects of the ABCA1 inducer R3R01 on albuminuria levels in diabetic kidney disease - R3R01-DKD-201
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
An Exploratory Pharmacokinetic Study to Evaluate the Exposure of R3R01 afterAdministration as New Polymorph in Healthy Subjects
100 Clinical Results associated with River 3 Renal Corp.
0 Patents (Medical) associated with River 3 Renal Corp.
100 Deals associated with River 3 Renal Corp.
100 Translational Medicine associated with River 3 Renal Corp.